Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
RESEARCH TOOLSreports
Holding BOLT?
Track your performance easily
BOLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.49 - $1.56
Previous Close$0.5
Volume70.08K
Average Volume (3M)148.06K
Market Cap
$19.14M
Enterprise Value-$16.48M
Total Cash (Recent Filing)$53.80M
Total Debt (Recent Filing)$18.18M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 26, 2025EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding38,273,002
10 Day Avg. Volume204,235
30 Day Avg. Volume148,062
Standard Deviation0.20
R-Squared0.05
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.27
Price to Sales (P/S)1.96
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.69
Enterprise Value/Gross Profit-2.09
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$1.75Price Target Upside250.00% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bolt Biotherapeutics News
PremiumCompany Announcements
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look
PremiumCompany Announcements
Bolt Biotherapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBDC-3042 has progressed to its final Phase 1 monotherapy dose level with no observed dose-limiting toxicities and signs of dose-dependent pharmacodynamics.
Financial StabilityThe company had $84.4M in cash and equivalents, with management expecting a cash runway through mid-2026.
Preclinical ResearchPreclinical work with BDC-4182 demonstrated efficacy across several preclinical models.
Bears Say
Analyst RatingAnalyst maintains a Neutral rating and has no price target as more clarity on the company's pipeline is awaited.
Clinical TrialsThe stock is expected to remain pressured until clinical trials play out in 2025.
Financial PerformanceBolt reported 3Q24 revenue of $1.1M and EPS of ($0.40), compared to estimates of $1.7M and ($0.38), respectively.
---
Ownership Overview
11.18%
Insiders
3.96% Mutual Funds
42.35% Other Institutional Investors
39.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $0.48 and its highest was $1.56 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Currently, no data Available
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 94 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.06.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics does not currently pay dividends.
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -$0.37.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 38,273,003 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Among the largest hedge funds holding Bolt Biotherapeutics’s share is Hawkeye Capital Management, LLC. It holds Bolt Biotherapeutics’s shares valued at 269K.
---
Bolt Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.75 (250.00% Upside)
$1.75 (250.00% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.49%
12-Months-Change
Fundamentals
Return on Equity
-64.99%
Trailing 12-Months
Asset Growth
-37.65%
Trailing 12-Months
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
---
BOLT Stock 12 Month Forecast
Average Price Target
$1.75
▲(250.00% Upside)
Technical Analysis
---